Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cyclophosphamide offers superior GVHD prophylaxis

Bolaños-Meade J et al. 2018 BMT Tandem Meetings, Abstract LB1.

Key clinical point: A cyclophosphamide-containing posttransplant regimen bested controls for reducing graft versus host disease rates.

Major finding: The hazard ratio for GVHD-free and relapse-free survival was 0.72 for those receiving cyclophosphamide, compared with controls (P = .04).

Study details: Randomized, controlled trial of 497 patients receiving one of three intervention arm posttransplant regimens for GVHD prophylaxis, or a control regimen of tacrolimus and methotrexate.

Disclosures: Dr. Bolaños-Meade reported serving on the data safety monitoring board of Incyte.

Source: Bolaños-Meade J et al. 2018 BMT Tandem Meetings, Abstract LB1.

Read the article.

Citation:

Bolaños-Meade J et al. 2018 BMT Tandem Meetings, Abstract LB1.

This Week's Must Reads

Observational study shows hydroxyurea well tolerated in sickle cell disease, Dauvergne B et al. FSCDR 2018, presentation JSCDH-D-18-00052

Large cohort study demonstrates DOAC safety vs. warfarin , Vinogradova Y et al. BMJ 2018;362:k2505.

Oral administration of arsenic + ATRA effective for APML, Zhu HH et al. Lancet Oncol. 2018;19:871-9.

Must Reads in Cellular Therapy

Blood type is diarrhea destiny, Kumar P et al. J Clin Invest. 2018 May 17; doi: 10.1172/JCI97659.

Fertility poor irrespective of conditioning regimen for transplants , Oquendo del Toro H et al. The 2018 Bone Marrow Transplant Tandem Meetings, Abstract 88.

Relapse triggers high rate of haploidentical donor graft failure, Yanir AD et al. Biol Blood Marrow Transplant. doi: 10.1016/j.bbmt.2018.03.001.

Atovaquone associated with increased nocardiosis risk, Molina A et al. Acute Leukemia Forum 2018, Poster Session.